Biodegradable scaffolds are minimally invasive medical devices that are used to open and support blocked arteries. They are made from bioabsorbable materials that slowly break down in the body after artery-opening procedure. These scaffolds are commonly used in treatment of peripheral artery disease that causes narrowing of arteries in legs.

The global biodegradable scaffold market is estimated to be valued at US$ 2.31 Bn in 2023 and is expected to exhibit a CAGR of 4.1%  over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

Rising cases of critical limb ischemia is a major driver for growth of biodegradable scaffold market. Critical limb ischemia refers to severe obstruction of arteries that significantly reduces blood flow to legs and feet. If left untreated, it can lead to ulcers and gangrene, requiring major amputation. With increasing risk factors like diabetes, obesity and growing geriatric population, cases of critical limb ischemia have been rising globally. According to estimates from National Institutes of Health, over 10 million people in the US suffer from peripheral artery disease with around 20% of them having critical limb ischemia. Biodegradable scaffolds are preferred minimally invasive treatment option for critical limb ischemia as they support blocked arteries and facilitate blood flow restoration without need for major surgery.

Growing preference for minimally invasive treatment procedures is another key factor fueling demand for biodegradable scaffolds. Compared to open surgeries, minimally invasive procedures using scaffolds offer benefits like reduced post-operative complications, shorter hospital stay and faster recovery time. This has driven uptake of biodegradable scaffolds among physicians and patients for treatment of various artery blockages. Manufacturers are also undertaking efforts to develop advanced biodegradable scaffolds with enhanced deliverability and longer patency, in order to strengthen their market position.

SWOT Analysis
Strength: Biodegradable scaffold is derived from natural sources and breaks down gradually within the body without requiring removal. This reduces postoperative complications and reoperations. It effectively supports new cell growth and tissue regeneration. Biodegradable polymers mimic the extracellular matrix and facilitate the attachment, migration, and proliferation of cells.
Weakness: Production cost of biodegradable scaffold is higher than synthetic scaffolds. Limited availability and restricted sources of biodegradable polymers affect large-scale production. Mechanical strength and degradation rate depend on manufacturing technique and requires precise control.
Opportunity: Rising demand for minimally invasive procedures in tissue engineering and regenerative medicine. Growing geriatric population suffering from chronic diseases expands market potential. Accumulating clinical data establishing superiority over synthetic alternatives for specific applications.
Threats: Stringent regulatory approval process delays market entry of new products. Reimbursement policies pose challenges in commercialization. Increased competition from synthetic polymer-based tissue scaffolds.

Key Takeaways
The global Biodegradable Scaffold Market Share is expected to witness high growth. The market size was valued at US$ 2.31 Mn  in 2024 and is anticipated to grow at a CAGR of 4.1%  during the forecast period of 2024 to 2031.

Regional analysis
North America currently dominates the market attributed to advanced healthcare infrastructure and favorable reimbursement policies. Asia Pacific shows lucrative potential for growth led by widening patient pool in China and India coupled with local manufacturing initiatives and investment by global medtech giants.

Key players
Key players operating in the biodegradable scaffold market are Medtronic Plc, Koninklijke Philips N.V., Abbott, Johnson & Johnson Service Inc., Merit Medical Systems, Inc., Stryker, Penumbra, Inc., Acandis GmbH & Co. KG, MicroPort Scientific Corporation, Terumo Corporation, Cerus Endovascular Limited., ASAHI INTECC USA, INC., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., iVascular, LifeHealthcare, Veiva, and Nordson MEDICAL.

Check below related articles on this topic: https://www.newsanalyticspro.com/the-global-biodegradable-scaffold-market-growth/

https://whotimes.com/beyond-dna-exploring-the-frontier-of-creation-through-the-lens-of-synthetic-biology/